Which racetam has the strongest evidence?

Racetams are a family of synthetic compounds built around a 2-pyrrolidone “racetam” core. The original member, piracetam, has been marketed for decades in parts of Europe and elsewhere for a grab-bag of neurological indications—while also becoming a staple of the modern “nootropics” scene. Newer analogues—aniracetam, oxiracetam, pramiracetam, nefiracetam, and others—were developed to tweak potency, pharmacokinetics, or receptor activity.

The popular story is simple: racetams “enhance cognition.” The clinical literature tells a more complicated—and more interesting—story: signals of benefit appear most often in specific neurological conditions (for example, rehabilitation after brain injury, or cortical myoclonus), while evidence for broad cognitive enhancement in healthy people remains thin.

Racetam Neurological Effects

Mechanistically, racetams are not classic stimulants, and they do not act like amphetamines or methylphenidate. Across preclinical and human research, proposed neurological effects include:

Modulation of glutamatergic signalling, especially AMPA-related pathways (often described as “AMPA modulation” in the nootropics literature).
Cholinergic interactions, sometimes inferred from scopolamine challenge studies (where cognition is pharmacologically impaired).
Changes in neuronal membrane properties and cerebral microcirculation, particularly for piracetam—often framed as effects on membrane fluidity and blood rheology.
Neurorehabilitation-adjacent effects (plasticity, network reorganisation) that are hard to separate from natural recovery and therapy intensity in clinical settings.

These hypotheses are biologically plausible, but plausibility is not efficacy. The most useful way to assess racetams is therefore indication by indication, compound by compound, and with an eye on trial quality.

Piracetam Evidence

A recent meta-analysis of clinical trials in adults with memory impairment found no clear advantage for piracetam over placebo for memory outcomes: standardized mean difference (SMD) 0.75, with a very wide confidence interval 95% CI −0.19 to 1.69, p = 0.12, and extreme heterogeneity (I² = 96%) across 18 studies (886 participants).

In other words, the pooled estimate trends positive, but the data are too inconsistent to conclude that piracetam reliably improves memory. (Felipe Araujo Gouhie et al. 2024)

Older systematic reviews in dementia/cognitive impairment reach a similar bottom line, albeit with a nuance that explains why piracetam retained clinical attention for so long: “global” clinician impressions sometimes looked better even when objective cognitive tests did not.

A Cochrane review reported an odds ratio for improvement on global impression outcomes of OR 3.43 (95% CI 2.32 to 5.07), but also noted no significant differences on more specific cognitive measures and raised concerns about unpublished/untraceable data and possible publication bias. (Lindsey Flicker et al. 2004)

Acute ischaemic stroke

Piracetam’s most ambitious test was the large multicentre PASS trial in acute ischaemic stroke. In the full intention-to-treat population (n = 927), outcomes were essentially the same on the primary neurological scale at 4 weeks (Orgogozo 57.7 vs 57.6) and similar on functional status at 12 weeks (Barthel Index 55.8 vs 53.1)—but mortality numerically favoured placebo: 23.9% (111/464) vs 19.2% (89/463), RR 1.24 (95% CI 0.97 to 1.59), p = 0.15. (P P De Deyn et al. 1997)

The trial also reported post-hoc analyses suggesting that people treated earlier might do better. In an “early treatment” subgroup, the Barthel Index at 12 weeks was higher with piracetam (58.6 vs 49.4, p = 0.02), and the Orgogozo scale trended in the same direction (60.4 vs 54.9, p = 0.07). But because these were post-hoc analyses, they are hypothesis-generating rather than definitive.

Cochrane’s later update (three trials, 1002 patients) concluded there was no conclusive evidence of benefit and noted a non-significant trend toward increased early death (about 31% relative increase at one month before severity correction in the largest trial), underscoring how sensitive conclusions can be to baseline imbalances in stroke severity. (Stefano Ricci et al. 2012)

Post-stroke aphasia

A focused meta-analysis of seven RCTs (261 participants) in post-stroke aphasia found no significant improvement in overall aphasia severity at trial endpoints (SMD 0.23, 95% CI −0.03 to 0.49, p = 0.08). There was a statistically significant improvement on written language subtests (SMD 0.35, 95% CI 0.04 to 0.66, p = 0.03), suggesting any benefit may be modest and domain-specific. (J Zhang et al. 2016)

Cortical myoclonus

Piracetam’s strongest evidence base is not “nootropic” in the lifestyle sense, but neurological symptom control. In a placebo-controlled double-blind crossover trial of 21 patients with cortical myoclonus, 10/21 patients needed “rescue” during the placebo phase due to severe worsening, while none required rescue during piracetam. The total rating score improved with piracetam by a median of 22%. (P Brown et al. 1993)

Aniracetam

Aniracetam is often described as more “AMPA-active” than piracetam and is widely marketed online for memory and mood. But most controlled clinical work is decades old and often hard to access in full.

In a double-blind RCT in Alzheimer-type dementia (109 patients, 6 months), authors reported significant improvements in “psychobehavioural parameters” versus placebo, with “excellent” tolerability—but the abstract does not provide effect sizes. (Senin et al. 1991)
In another small randomized trial (44 patients, 3 months), there was no difference in clinical efficacy between aniracetam and placebo, and confusion led to treatment interruption in 4 aniracetam cases vs 1 placebo case. (Leif B Sourander et al. 1987)

A more modern paper sometimes cited for aniracetam is a comparative open study (not placebo-controlled) in mild dementia. In a subgroup with baseline MMSE 15–25 (n = 151), aniracetam had marginally better MMSE at 6 months than cholinesterase inhibitors (21.8 ± 3.6 vs 18.7 ± 4.2, p = 0.05) and better functional scores at 3 months (FRSSD 6.1 ± 4.6 vs 10.0 ± 4.7, p = 0.04). (Christina C Koliaki et al. 2011)
Because it is open-label and involves baseline imbalances the authors had to statistically manage, this is suggestive but not definitive evidence.

Oxiracetam and L-oxiracetam

Classic oxiracetam studies in dementia were typically small, 1980s–1990s era RCTs. For example, a double-blind placebo-controlled trial in mild–moderate dementia (40 outpatients, 90 days, 800 mg twice daily) reported significant between-group improvements across MMSE and several neuropsychological measures, with “no side effects observed” in the abstract. (C Villardita et al. 1987)

Another trial (65 enrolled, 58 completed) reported QoL benefits (p < 0.01) and adverse effects in 4 oxiracetam patients vs 1 placebo patient, with 2 withdrawals for tolerability. (G Bottini et al. 1992) These are signals—but from a period when trial standards and reporting were less rigorous than today.

What changes the picture is a recent, large, multicentre, randomized, double-blind phase 3 trial of L-oxiracetam (the active enantiomer) in mild-to-moderate traumatic brain injury. Between 2019 and 2024, 590 patients were randomized to L-oxiracetam, racemic oxiracetam, or placebo. The primary outcome was change in the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) score at 90 days.

LOTCA change (least-squares mean) at 90 days:
20.45 (L-oxiracetam) vs 11.47 (placebo)
Difference 8.97 (95% CI 5.69 to 12.26), p < 0.001
L-oxiracetam also outperformed oxiracetam by 4.54 points (95% CI 1.85 to 7.23).
A secondary cognitive measure (MoCA) showed a small advantage vs placebo at 90 days: difference 1.11 (95% CI 0.08 to 2.14).
Adverse events (any grade) were common but similar across groups: 65.96% (L-oxiracetam) vs 67.23% (placebo). Serious adverse events were numerically lower with L-oxiracetam (5.53%) than placebo (12.60%), though not statistically significant in the reported comparison (p = 0.100). (T Liu et al. 2025)

This is arguably the strongest modern randomized evidence for a “racetam-like” agent improving cognitive test performance—but it is in TBI recovery, not in healthy individuals.

Pramiracetam

One of the few “healthy volunteer” paradigms for racetams uses scopolamine, which reliably impairs aspects of memory and attention. In a trial with two groups of 12 healthy men (younger and older), pramiracetam 600 mg twice daily for 10 days partially reduced scopolamine-induced amnesia on episodic memory and attention tests. (M Mauri et al. 1994)

The limitation is that “partially reduced” does not automatically translate into meaningful enhancement above baseline, and many such studies are small and selectively reported.

Nefiracetam

Nefiracetam has been tested in post-stroke neuropsychiatric symptoms with mixed findings. In a randomized placebo-controlled study of post-stroke apathy, recruitment challenges meant only 13 participants were randomized; overall Apathy Scale scores decreased by a mean of 7.0 points, but there was no significant between-group difference at 12 weeks. (Sergio E Starkstein et al. 2016)

For compounds often discussed online—phenylpiracetam (fonturacetam), omberacetam, coluracetam, and others—high-quality, peer-reviewed RCT evidence for cognitive enhancement in healthy people is limited, not easily accessible, or absent from mainstream clinical databases. In practice, this means marketing claims frequently outpace what can be responsibly inferred from published clinical trials.

Racetams as nootropics

The strongest evidence from when cognition is impaired by a neurological condition, and when the trial is modern and well-designed. The L-oxiracetam TBI trial is the standout example, with an ~9-point advantage over placebo on LOTCA change at 90 days. (Liu et al. 2025)
For broad cognitive enhancement in healthy people, the evidence base is small and indirect. Scopolamine reversal studies suggest some capacity to modulate memory systems, but that is not the same as reliably boosting cognition above baseline in everyday life. (Mauri et al. 1994)
For chronic age-related memory complaints and dementia, piracetam’s clinical record is mixed and methodologically messy, with newer meta-analytic summaries emphasizing uncertainty and heterogeneity rather than clear benefit. (Gouhie et al. 2024; Flicker et al. 2004)
For post-stroke aphasia, pooled effects look small and may be limited to written language, not global language recovery. (Zhang et al. 2016)
For certain neurological symptoms like cortical myoclonus, piracetam has meaningful clinical effects, which is a different (but real) kind of “brain benefit.” (Brown et al. 1993)

References

1) Gouhie FA, et al. Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2024. “https://pubmed.ncbi.nlm.nih.gov/38878641/”

2) Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2004. “https://pmc.ncbi.nlm.nih.gov/articles/PMC12016011/”

3) De Deyn PP, et al. Treatment of acute ischemic stroke with piracetam (PASS trial). Stroke. 1997. “https://pubmed.ncbi.nlm.nih.gov/9412612/”

4) Ricci S, et al. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2012. “https://pmc.ncbi.nlm.nih.gov/articles/PMC7034527/”

5) Zhang J, et al. Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs. 2016. “https://pubmed.ncbi.nlm.nih.gov/27236454/”

6) Brown P, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord. 1993. “https://pubmed.ncbi.nlm.nih.gov/8419809/”

7) Sawires H, Botrous O. Double-blind, placebo-controlled trial on the effect of piracetam on breath-holding spells. Eur J Pediatr. 2012. “https://pubmed.ncbi.nlm.nih.gov/22302459/”

8) Akhondzadeh S, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev. 2008. “https://pubmed.ncbi.nlm.nih.gov/17929164/”

9) Lobaugh NJ, et al. Piracetam therapy does not enhance cognitive functioning in children with Down syndrome. Arch Pediatr Adolesc Med. 2001. “https://jamanetwork.com/journals/jamapediatrics/fullarticle/190511”

10) Senin U, et al. Aniracetam (Ro 13-5057) in the treatment of senile dementia of the Alzheimer type: a placebo-controlled multicentre study. Aging (Milano). 1991. “https://pubmed.ncbi.nlm.nih.gov/1822317/”

11) Sourander LB, et al. Senile dementia of the Alzheimer type treated with aniracetam: a double-blind study. Acta Neurol Scand. 1987. “https://pubmed.ncbi.nlm.nih.gov/3103163/”

12) Koliaki CC, et al. Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study. CNS Neurosci Ther. 2011. “https://pmc.ncbi.nlm.nih.gov/articles/PMC6493642/”

13) Villardita C, et al. Clinical and neuropsychological study with oxiracetam in patients with dementia. Int J Clin Pharmacol Res. 1987. “https://pubmed.ncbi.nlm.nih.gov/3479527/”

14) Bottini G, et al. Oxiracetam in dementia: a double-blind, placebo-controlled study. Acta Neurol Scand. 1992. “https://pubmed.ncbi.nlm.nih.gov/1414239/”

15) Liu T, et al. Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial. Signal Transduct Target Ther. 2025. “https://www.nature.com/articles/s41392-025-02492-5”

16) Mauri M, et al. Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers. (journal indexed on PubMed). 1994. “https://pubmed.ncbi.nlm.nih.gov/15374306/”

17) Starkstein SE, et al. A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam for Poststroke Apathy. (journal indexed on PubMed). 2016. “https://pubmed.ncbi.nlm.nih.gov/26915605/”

18) Cohen PA, et al. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. (full text in PMC). 2021. “https://pmc.ncbi.nlm.nih.gov/articles/PMC8382366/”